Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Changing Spectrum of the Cutaneous Manifestations of HIV Disease

The Changing Spectrum of the Cutaneous Manifestations of HIV Disease EDITORIAL The Changing Spectrum of the Cutaneous Manifestations of HIV Disease UTANEOUS MANIFESTATIONS of human im- cally causes profound and sustained suppression of viral munodeficiency virus (HIV) infection replication, reducing morbidity and prolonging life in pa- and acquired immunodeficiency syn- tients with HIV infection. Thus, it is now recommended drome (AIDS) have been the topic of that all patients begin combination therapy with a regi- C much interest since the syndrome was men that includes a PI at the time of initial diagnosis of 5,6 first described in the early 1980s. In fact, it was Kaposi HIV infection. sarcoma (KS) of the skin in young homosexual men, ini- Four HIV PIs are currently available: indinavir sul- tially described in part by a dermatologist, that first fate (Crixivan), nelfinavir (Viracept), ritonavir (Nor- 6,7 sparked the interest in AIDS itself. As has been empha- vir), and saquinavir mesylate (Invirase and Fortovase). sized repeatedly in the medical literature and as Spira and Some of the nucleoside reverse transcriptase inhibitors colleagues remind us in this issue of the ARCHIVES, skin administered in combination with PIs include zidovu- disorders are extremely common in these individuals, and dine (AZT or Retrovir), didanosine (Videx), stavudine in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

The Changing Spectrum of the Cutaneous Manifestations of HIV Disease

JAMA Dermatology , Volume 134 (10) – Oct 1, 1998

Loading next page...
 
/lp/american-medical-association/the-changing-spectrum-of-the-cutaneous-manifestations-of-hiv-disease-wfX7Mp5Xxs
Publisher
American Medical Association
Copyright
Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/archderm.134.10.1290
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL The Changing Spectrum of the Cutaneous Manifestations of HIV Disease UTANEOUS MANIFESTATIONS of human im- cally causes profound and sustained suppression of viral munodeficiency virus (HIV) infection replication, reducing morbidity and prolonging life in pa- and acquired immunodeficiency syn- tients with HIV infection. Thus, it is now recommended drome (AIDS) have been the topic of that all patients begin combination therapy with a regi- C much interest since the syndrome was men that includes a PI at the time of initial diagnosis of 5,6 first described in the early 1980s. In fact, it was Kaposi HIV infection. sarcoma (KS) of the skin in young homosexual men, ini- Four HIV PIs are currently available: indinavir sul- tially described in part by a dermatologist, that first fate (Crixivan), nelfinavir (Viracept), ritonavir (Nor- 6,7 sparked the interest in AIDS itself. As has been empha- vir), and saquinavir mesylate (Invirase and Fortovase). sized repeatedly in the medical literature and as Spira and Some of the nucleoside reverse transcriptase inhibitors colleagues remind us in this issue of the ARCHIVES, skin administered in combination with PIs include zidovu- disorders are extremely common in these individuals, and dine (AZT or Retrovir), didanosine (Videx), stavudine in

Journal

JAMA DermatologyAmerican Medical Association

Published: Oct 1, 1998

References